Our precision therapies target insulin-dependent diabetes, featuring a mAb43 monotherapy and an array of combination therapies utilizing islet-directed antibody-drug conjugates (ADCs).

 

These multifunctional biologics comprise four interconnected modules:

1. An islet-homing module guiding systematically administered ADCs to pancreatic islets.

2. A mitogenic module stimulating adult beta cell growth.

3. A cell-surface masking module providing a protective shield against autoimmune attacks in T1D.

4. A stress-alleviating module designed to protect β-cells from inflammation-induced apoptosis in T2D. 

​

​